MedTrace Logo

Nicotine Treatment of Impulsivity in Parkinson's Disease

NCT01216904 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-05-14

No results posted yet for this study

Summary

The specific aims of this study are to examine whether treatment with transdermal nicotine improves computer-based laboratory and clinical measures of impulsive and compulsive behaviors in Parkinson's Disease subjects who have recently experienced an impulse control disorder.

Conditions

Interventions

DRUG

nicotine patch

7 mg patches to be worn for 16 hours per day

DRUG

placebo

placebo patch to be worn 16 hours per day

Sponsors & Collaborators

  • Parkinson's Disease Foundation

    collaborator OTHER

  • The Parkinson Study Group

    collaborator NETWORK

  • University of Vermont

    lead OTHER

Principal Investigators

  • James Boyd, MD · UVM/FAHC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216904 on ClinicalTrials.gov